02 August 2020
Visiongain has launched a new pharma report Cancer Supportive Care Drugs Market Report 2020-2030: Prospects by Drug Class (G-CSFs, Erythropoietin Stimulating Agents (ESA), Antiemetics, Bisphosphonates, Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Others), Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Other Cancers), and Geography.
The global cancer supportive care drugs market is projected to grow at a lucrative CAGR of xx% and anticipated to surpass USD xx billion by 2030.
Supporting treatment for cancer, also known as palliative care, focuses on relieving patients from cancer therapy side effects. Supporting medications are used in cancer palliative care to reduce the side effects of cancer treatments. Treatments for cancer need to be discontinued in many cases or doses need to be decreased due to various reasons such as low numbers of blood cells. In such cases, cancer-friendly drugs such as CSFs allow patients to continue cancer therapies as well as in other cases, allowing higher doses of cancer therapies.
Cancer has been primarily leading causes of death worldwide and most treatments for cancer come with various side effects such as pain, fatigue, anxiety, issues with fertility, sexual problems, heartburn, and bone disease among other side effects. With such side effects, during cancer treatments, it is best to use supportive care medications. These factors are expected to drive the demand for cancer supportive care drugs over the forecast period.
There were approximately 18 million new cancer cases and approximately 9 million deaths reported globally in 2018, according to the World Health Organization. Also, statistics report increasing cancer prevalence over the years. This has resulted in an increase in the number of cancer therapies among patients.
Supporting drugs for cancer care are used to reduce the side effects of cancer therapy. Increasing cancer prevalence can, therefore, be directly linked to this market's growth. Increasing disposable income and improved healthcare structure have also helped people access the medicines that support cancer care.
Technological advances, however, are being adopted at a faster rate in targeted therapy drugs that have fewer side effects than traditional cancer therapy drugs. This has had a direct impact on the development of the market. However, stringent regulatory processes are anticipated to impede the market growth.
In the year 2018, North America dominated the cancer supportive care drugs by capturing over 35% of global market share. The dominance of the North American region is attributed to growing cancer prevalence cases in the region. As per the reports of the National Cancer Institute, approximately 1.7 million fresh cancer cases were diagnosed in the United States and 609,640 people died from the disease. Moreover, as per the latest edition of Canadian Cancer Statistics 2019; an estimated 220,440 cancer cases were diagnosed in 2019 out of which lung cancer was the most commonly diagnosed cancer. The growing cancer cases in the United States and Canada are anticipated to lead to a burden on the overall population, hence the US and Canadian healthcare system is spending heavily on treatment and research in the oncology field.
Furthermore, the Asia Pacific region is anticipated to grow with the highest CAGR over the forecast period owing to the growing patient pool, rising cancer incidence, and penetration of major pharmaceutical & biotech companies in emerging economies of Japan, China & India.
Some of the major players operating in this industry are AbbVie Inc., Acacia Pharma, Amgen, Apr Applied Pharma Science Research, Astellas Pharma Inc., AstraZeneca PLC, Baxter International, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche LTD., Fagron Group., Johnson & Johnson, Kyowa Hakko Kirin, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceuticals Industries among other prominent players.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Gene Amplification Technologies market was valued at US$4,587 million in 2022 and is projected to grow at a CAGR of 9.8% during the forecast period 2023-2033.
05 December 2022
The global stem cell technologies and applications market was valued at US$9,247 million in 2021 and is projected to grow at a CAGR of 8.9% during the forecast period 2022-2032.
01 December 2022
The biosimilars and follow-on biologics market is valued at US$19,668.3 million in 2022 and is projected to grow at a CAGR of 31.14% during the forecast period 2023-2033.
01 December 2022
The Medical Imaging market was valued at US$38.6 billion in 2021 and is projected to grow at a CAGR of 5.46% during the forecast period 2022-2032.